R21: Cancer Therapeutics B – ATC (83)
The Cancer Therapeutics-B special emphasis panel focuses on translational and clinical investigations that encompass cancer therapeutic development and cancer treatment. Applications that promote new therapeutic strategies for addressing neoplastic diseases (including solid tumors and leukemias) that extend foundational work by evaluating therapeutic efficacy and preclinical safety/toxicity
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Evaluation of gene and drug-delivery strategies (nonimmunological), including reformulation/combination of existing drugs or formulation development of evidence based new drugs
- Preclinical drug toxicity and PK/PD studies in small, medium, large, patient-derived xenograft, or transgenic animal models, or human specimens for validation.
- Late-stage diversification and optimization of small molecule anti-cancer agents.
- Development of therapeutic strategies and rational combinations of cytotoxic drugs with novel agents including those targeting growth factors, signaling, cell cycle regulation, angiogenic, and differentiation pathways.
- Early-stage, pilot clinical trials of novel anticancer therapeutic and drug-delivery strategies involving pharmacokinetic, pharmacodynamic, toxicologic, or pharmacogenomic endpoints.
- Development and application of mathematical and computational methods for the investigation of therapeutic strategies.
